Corticotropin-releasing factor (CRF) and
serotonin are important transmitters of the pathophysiology of
mood disorder. To clarify the mechanisms of action of
lamotrigine (LTG) and
carbamazepine (CBZ), we determined their effects on
serotonin release associated with CRF in rat dorsal raphe nucleus (DRN) and median prefrontal cortex (mPFC) using dual-probe microdialysis. Neither perfusion with CRF1 nor CRF2 antagonists into DRN-affected
serotonin release in DRN and mPFC. Perfusion of 10 μM CRF into DRN increased
serotonin release in both regions, whereas 0.1 μM CRF decreased and had no effect on
serotonin release in DRN and mPFC, respectively. Pre-perfusion with CRF1 antagonist into DRN inhibited 0.1 μM CRF-induced
serotonin reduction, whereas pre-perfusion with CRF2 antagonist in DRN inhibited 10 μM CRF-induced
serotonin elevation, without affecting 0.1 μM CRF-induced
serotonin reduction. LTG perfusion concentration dependently decreased
serotonin releases in DRN and mPFC. Therapeutic and supratherapeutic concentrations of CBZ increased and decreased
serotonin releases in both regions, respectively. Pre-perfusion with sub-therapeutic concentration LTG inhibited CRF1-induced
serotonin reduction without affecting CRF2-induced
serotonin release, whereas pre-perfusion with therapeutic concentration of LTG inhibited both CRF1- and CRF2-actions. In contrast, both therapeutic and supratherapeutic concentrations of CBZ inhibited CRF2-induced
serotonin release without affecting CRF1-induced
serotonin reduction. Neither LTG nor CBZ affected the CRF-induced cAMP production in cells over-expressing CRF1 and CRF2 receptors. This study demonstrated that inhibition of CRF2-receptor-mediated serotonergic transmission is a mechanism shared by LTG and CBZ, two clinically related compounds, whereas LTG but not CBZ inhibits CRF1-receptor-mediated serotonergic transmission. Therefore, these mechanisms may contribute to the clinical actions of these agents.